TGFB1 and pulmonary fibrosis: In the bleomycin-induced pulmonary fibrosis mouse model, dasatinib, an inhibitor of the TGF-β/Smad pathway, can inhibit the EMT of mouse alveolar and bronchial epithelial cells, thereby slowing down the progress of pulmonary fibrosis by reducing the reaction with SIgA [91].